MEF2D and plasma cell myeloma: Increased lncRNA H19 expression induces bortezomib resistance in multiple myeloma by upregulating MCL-1 via sponging miR-29b-3p [24] LncR-D63785 acts as a competitive endogenous RNA of miR-422a and promotes chemotherapy resistance by blocking miR-422-dependent suppression of MEF2D in gastric cancer [27].